Evidence map›Paper›PMID 33185110›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2021

Inhibition of ATGL in adipose tissue ameliorates isoproterenol-induced cardiac remodeling by reducing adipose tissue inflammation.

Shingo Takahara, Mourad Ferdaoussi, Nikola Srnic, Zaid H Maayah, Shubham Soni, Anna K Migglautsch, Rolf Breinbauer, Erin E Kershaw, Jason R B Dyck

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Mechanical interplay between adipose tissues and disease progression.Bioengineering & translational medicine · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Small-Molecule Inhibitors Targeting Lipolysis in Human Adipocytes.Journal of the American Chemical Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 4 countries.

Shingo TakaharaCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-8363-293X
Mourad FerdaoussiCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
Nikola SrnicCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
Zaid H MaayahCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
Shubham SoniCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
Anna K MigglautschInstitute of Organic Chemistry, Graz University of Technology, Graz, Austria.
Rolf BreinbauerInstitute of Organic Chemistry, Graz University of Technology, Graz, Austria.ORCID 0000-0001-6009-7359
Erin E KershawDivision of Endocrinology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-3887-4868
Jason R B DyckCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
University of Alberta · CAGraz University of Technology · ATUniversity of Pittsburgh · US

Funding

Adipose Triglyceride Lipase (ATGL) in Lipotoxicity and The Metabolic SyndromeR01DK090166 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KERSHAW, ERIN E. · 2011 to 2015
$1.7M
Adipocyte lipolysis, adipose tissue function, and lipodystrophyR56DK090166 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KERSHAW, ERIN E. · 2016 to 2016
$116k
NIDDK NIH HHS R01 DK090166NIDDK NIH HHS R56 DK090166
6 · The paper itself

Abstract

Following cardiac injury, increased adrenergic drive plays an important role in compensating for reduced cardiac function. However, chronic excess adrenergic stimulation can be detrimental to cardiac pathophysiology and can also affect other organs including adipose tissue, leading to increased lipolysis. Interestingly, inhibition of adipose triglyceride lipase (ATGL), a rate-limiting enzyme in lipolysis, in adipocytes ameliorates cardiac dysfunction in a heart failure model. Thus, we investigated whether inhibition of adipocyte ATGL can mitigate the adverse cardiac effects of chronic adrenergic stimulation and explored the underlying mechanisms. To do this, isoproterenol (ISO) was continuously administered to C57Bl/6N mice for 2 wk with or without an ATGL inhibitor (Atglistatin). We found that Atglistatin alleviated ISO-induced cardiac remodeling and reduced ISO-induced upregulation of galectin-3, a marker of activated macrophages and a potent inducer of fibrosis, in white adipose tissue (WAT), heart, and the circulation. To test whether the beneficial effects of Atglistatin occur via inhibition of adipocyte ATGL, adipocyte-specific ATGL knockout (atATGL-KO) mice were utilized for similar experiments. Subsequently, the same cardioprotective effects of atATGL-KO following ISO administration were observed. Furthermore, Atglistatin and atATGL-KO abolished ISO-induced galectin-3 secretion from excised WAT. We further demonstrated that activation of cardiac fibroblasts by the conditioned media of ISO-stimulated WAT is galectin-3-dependent. In conclusion, the inhibition of adipocyte ATGL ameliorated ISO-induced cardiac remodeling possibly by reducing galectin-3 secretion from adipose tissue. Thus, inhibition of adipocyte ATGL might be a potential target to prevent some of the adverse effects of chronic excess adrenergic drive.

Indexed as

IsoproterenolAcyltransferasesAdipose Tissue, WhiteAnimalsAnti-Inflammatory AgentsCells, CulturedDisease Models, AnimalEnzyme InhibitorsFibroblastsGalectin 3Heart DiseasesInflammation MediatorsLipaseLipolysisMaleMiceAcyltransferasesAnti-Inflammatory AgentsatglistatinEnzyme InhibitorsGalectin 3Inflammation MediatorsIsoproterenolLgals3 protein, mouseLipasePhenylurea CompoundsPNPLA2 protein, mouseadipose triglyceride lipaseATGLcardiac remodelinggalectin-3inflammationisoproterenol

Identifiers

PMID33185110
PMCPMC7847076
OpenAlexW3105786081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.